{"id":543884,"date":"2021-05-19T22:44:01","date_gmt":"2021-05-19T22:44:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=543884"},"modified":"2021-05-19T22:44:01","modified_gmt":"2021-05-19T22:44:01","slug":"surgical-site-infection-market-industry-analysis-cagr-pipeline-drugs-and-key-companies-by-delveinsight-zurex-pharma-dr-reddys-laboratories-botanix-pharma-menarini-group-pharma-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/surgical-site-infection-market-industry-analysis-cagr-pipeline-drugs-and-key-companies-by-delveinsight-zurex-pharma-dr-reddys-laboratories-botanix-pharma-menarini-group-pharma-and-others_543884.html","title":{"rendered":"Surgical Site Infection Market: Industry Analysis, CAGR, Pipeline, Drugs and Key Companies by Delveinsight | Zurex Pharma, Dr. Reddy&#8217;s Laboratories, Botanix Pharma, Menarini Group Pharma and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1621405351.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Surgical Site Infection Market: Industry Analysis, CAGR, Pipeline, Drugs and Key Companies by Delveinsight | Zurex Pharma, Dr. Reddy&#039;s Laboratories, Botanix Pharma, Menarini Group Pharma and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1621405351.jpeg\" alt=\"Surgical Site Infection Market: Industry Analysis, CAGR, Pipeline, Drugs and Key Companies by Delveinsight | Zurex Pharma, Dr. Reddy&#039;s Laboratories, Botanix Pharma, Menarini Group Pharma and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Surgical Site Infection Market<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8220;<strong>Surgical Site Infection Market<\/strong>&#8221; report provides a thorough comprehension of the Surgical Site Infection, historical and forecasted epidemiology, and the Surgical Site Infection market trends in the 7MM [the United States, EU5 (Germany,&nbsp;Spain,&nbsp;Italy,&nbsp;France, and&nbsp;United Kingdom) and&nbsp;Japan]. The Surgical Site Infection market report also proffers an analysis of the current Surgical Site Infection treatment algorithm\/practice, market drivers, market barriers, and unmet medical needs.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the vital takeaways of the&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/surgical-site-infections-ssi-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Surgical Site Infection Market Research Report<\/a>&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>A slew of companies such as&nbsp;<strong>Zurex Pharma, Dr. Reddy&#8217;s Laboratories Ltd., Botanix Pharma, Menarini Group Pharma, PolyPid, Destiny Pharma<\/strong>, and others are developing Surgical Site Infection therapies to influence treatment outlook.&nbsp;<\/li>\n<li>In&nbsp;Nov 2020,&nbsp;<strong>PolyPid Ltd<\/strong>. announced that&nbsp;<strong>D-PLEX100<\/strong>&nbsp;received&nbsp;<strong>Breakthrough Therapy Designation<\/strong>&nbsp;from the US Food and Drug Administration to prevent Surgical Site Infections in patients undergoing elective colorectal surgery.<\/li>\n<li>The prophylactic therapy segment is&nbsp;<strong>XF-73&nbsp;<\/strong>under development by&nbsp;<strong>Destiny Pharma<\/strong>&nbsp;with its antimicrobial &#8220;XF&#8221; drug platform. XF-73 was awarded&nbsp;<strong>QIDP&nbsp;<\/strong>status in&nbsp;October 2015.<\/li>\n<li>Presently the emerging therapies such as&nbsp;<strong>XF-73, D-PLEX100, DFA-02, BTX 1801, ZuraGard,&nbsp;<\/strong>and others are focused on treating or preventing Surgical Site Infection in either cardio or abdominal surgeries in the prophylactic segment, while&nbsp;<strong>Delafloxacin&nbsp;<\/strong>is used for the Surgical Site Infection treatment.&nbsp;<\/li>\n<li>Under the Surgical Site Infection treatment market,&nbsp;<strong>Delafloxacin&nbsp;<\/strong>by<strong>&nbsp;Menarini Group<\/strong>&nbsp;is the only upcoming therapy for a patient with incisional, superficial or deep, surgical site infection after cardiothoracic\/related leg or abdominal surgery.<\/li>\n<li><strong>Delafloxacin<\/strong>, under the name of&nbsp;<strong>Baxdela&nbsp;<\/strong>(fluoroquinolone antibacterial), received FDA approval for the Acute Bacterial Skin and Skin Structure Infections treatment, announced by&nbsp;<strong>Melinta Therapeutics&nbsp;<\/strong>in June 2017.&nbsp;<\/li>\n<li><strong>Menarini Group&nbsp;<\/strong>and&nbsp;<strong>Melinta<\/strong>&nbsp;<strong>Therapeutics<\/strong>&nbsp;entered into a co-development and commercial agreement in 68 Countries for&nbsp;<strong>Delafloxacin&nbsp;<\/strong>in 2017.&nbsp;<\/li>\n<li>The future development of new modalities in Surgical Site Infection treatment and prophylaxis appears promising during the forecast period of 2021&ndash;2030. Of the emerging therapies,&nbsp;<strong>XF-73, D-PLEX100, BTX 1801, Delafloxacin, DFA-02, Zuragard<\/strong>, and others are expected to change the Surgical Site Infection market scenario in the upcoming years.&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free Sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/surgical-site-infections-ssi-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/surgical-site-infections-ssi-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Surgical Site Infections (SSIs) are the most common nosocomial infection and frequently cause morbidity and mortality among patients of hospitals.&nbsp;<\/p>\n<p style=\"text-align: justify;\">As per DelveInsight&#8217;s research, the total&nbsp;Surgical Site Infection Incident cases&nbsp;in the 7MM were&nbsp;<strong>1,323,491<\/strong>&nbsp;cases in 2018. Moreover, it is observed that males and females are equally affected.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/surgical-site-infections-ssi-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Surgical Site Infection Emerging Therapies<\/a>&nbsp;Along with Key Players<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>XF-73: Destiny Pharma<\/li>\n<li>D-PLEX100: PolyPid<\/li>\n<li>Delafloxacin: Menarini Group Pharma<\/li>\n<li>BTX 1801: Botanix Pharma<\/li>\n<li>DFA-02: Dr Reddy&#8217;s Laboratories Ltd.<\/li>\n<li>Zuragard: Zurex Pharma&nbsp;<\/li>\n<li>And several others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a sample copy of this report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/surgical-site-infections-ssi-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/surgical-site-infections-ssi-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the&nbsp;Surgical Site Infection Market Insight Report&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Geography Covered:&nbsp;<\/strong>The United States, EU5 (Germany,&nbsp;France,&nbsp;Italy,&nbsp;Spain, and the&nbsp;United Kingdom), and Japan.&nbsp;<\/li>\n<li><strong>Study Period<\/strong>: 3-year historical and 10-year forecasted analysis (2018-2030).<\/li>\n<li><strong>Surgical Site Infection&nbsp;Markets Segmentation<\/strong>: By&nbsp;<strong>Geographies<\/strong>&nbsp;and By&nbsp;<strong>Surgical Site Infection&nbsp;Therapies&nbsp;<\/strong>(Historical and Forecasted, Current and Upcoming)&nbsp;<\/li>\n<li><strong>Dominant Market Companies investigating its candidates for&nbsp;Surgical Site Infection:&nbsp;<\/strong>Zurex Pharma, Dr. Reddy&#8217;s Laboratories Ltd., Botanix Pharma, Menarini Group Pharma, PolyPid, Destiny Pharma, and several others.&nbsp;<\/li>\n<li><strong>Analysis<\/strong>: Comparative and conjoint analysis of emerging therapies.&nbsp;<\/li>\n<li>Case Studies<\/li>\n<li>KOL&#8217;s Views<\/li>\n<li>Analyst&#8217;s View<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free Sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/surgical-site-infections-ssi-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/surgical-site-infections-ssi-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td valign=\"bottom\">\n<p><strong>1<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Surgical Site Infection Key Insights<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>2<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Surgical Site Infection Report Introduction<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>3<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Surgical Site Infection Prophylactic Market Overview at a Glance<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>4<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Surgical Site Infection Treatment Market Overview at a Glance<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>5<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Surgical Site Infection Executive Summary<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>6<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Surgical Site Infection Disease Background and Overview&nbsp;<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>7<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Surgical Site Infection&nbsp;Epidemiology and Patient Population<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>7.1<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>The United States<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>7.2<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>EU5 Countries<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>7.2.1<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Germany<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>7.2.2<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>France<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>7.2.3<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Italy<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>7.2.4<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Spain<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>7.2.5<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>The United Kingdom<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>7.3<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Japan<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>8<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Surgical Site Infection&nbsp;Treatment and Management&nbsp;<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>9<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Surgical Site Infection Prevention<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>10<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Organizations contributing towards Surgical Site Infection<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>11<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Surgical Site Infection Patient Journey<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>12<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Surgical Site Infection Case Report<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>13<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Surgical Site Infection&nbsp;Emerging Therapies<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>13.1<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>XF-73: Destiny Pharma<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>13.2<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>&nbsp;D-PLEX100: PolyPid<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>13.3<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Delafloxacin: Menarini Group Pharma<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>13.4<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>BTX 1801: Botanix Pharma<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>13.5<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>DFA-02: Dr. Reddy&#8217;s Laboratories Ltd.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>13.6<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Zuragard: Zurex Pharma<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>14<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>7MM Surgical Site Infection Market Analysis<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>14.1<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>The United States Surgical Site Infection Market Size<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>14.2<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>EU-5 Surgical Site Infection Market Size<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>14.2.1<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Germany Market Size<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>14.2.2<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>France Market Size<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>14.2.3<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Italy Market Size<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>14.2.4<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Spain Market Size<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p>14.2.5<\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>The United Kingdom Market Size<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>14.3<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Japan<\/strong>&nbsp;<strong>Surgical Site Infection Market Size<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>15<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Surgical Site Infection Market Drivers<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>16<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Surgical Site Infection Market Barriers<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>17<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>SWOT Analysis of Surgical Site Infection<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>18<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Surgical Site Infection Unmet Needs<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>19<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Appendix<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>20<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>DelveInsight Capabilities<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>21<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>Disclaimer<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>22<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p><strong>About DelveInsight<\/strong><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC:&nbsp;https:\/\/www.delveinsight.com\/sample-request\/surgical-site-infections-ssi-market<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><strong style=\"color: #000000; text-decoration: underline;\">About&nbsp;<\/strong>DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=surgical-site-infection-market-industry-analysis-cagr-pipeline-drugs-and-key-companies-by-delveinsight-zurex-pharma-dr-reddys-laboratories-botanix-pharma-menarini-group-pharma-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/surgical-site-infections-ssi-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/surgical-site-infections-ssi-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/surgical-site-infections-ssi-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=surgical-site-infection-market-industry-analysis-cagr-pipeline-drugs-and-key-companies-by-delveinsight-zurex-pharma-dr-reddys-laboratories-botanix-pharma-menarini-group-pharma-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Surgical Site Infection Market DelveInsight&#8217;s &#8220;Surgical Site Infection Market&#8221; report provides a thorough comprehension of the Surgical Site Infection, historical and forecasted epidemiology, and the Surgical Site Infection market trends in the 7MM [the United States, EU5 (Germany,&nbsp;Spain,&nbsp;Italy,&nbsp;France, and&nbsp;United Kingdom) &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/surgical-site-infection-market-industry-analysis-cagr-pipeline-drugs-and-key-companies-by-delveinsight-zurex-pharma-dr-reddys-laboratories-botanix-pharma-menarini-group-pharma-and-others_543884.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,451,417,423],"tags":[],"class_list":["post-543884","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Law-Legal","category-Marketing-Sales","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543884","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=543884"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543884\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=543884"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=543884"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=543884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}